Johnson & Johnson
267.08USD
-2.0400 (-0.76%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | 85.2B | 88.8B | 94.2B | 101.1B | 108.8B |
| Q1 | 19.8B | 20.9B | 21.4B | 21.9B | 24.1B | — |
| Q2 | 20.2B | 21.5B | 22.4B | 23.7B | 25.3B | — |
| Q3 | 20.0B | 21.4B | 22.5B | 24.0B | 25.2B | — |
| Q4 | — | 21.4B | 22.5B* | 24.6B* | 26.6B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | 13.72 | 5.79 | 11.03 | 11.05 | 12.31 |
| Q1 | 1.93 | -.030 | 1.34 | 4.54 | 2.14 | — |
| Q2 | 1.80 | 1.96 | 1.93 | 2.29 | 2.27 | — |
| Q3 | 1.68 | 10.21 | 1.11 | 2.12 | 2.42 | — |
| Q4 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.67 |
| 1.41* |
| 2.11* |
| 3.02 |
| — |